Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EXALGO vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mu-opioid receptor agonist; inhibits ascending pain pathways and alters pain perception and emotional response to pain.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatments are inadequate
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Initial: 8 mg orally every 24 hours for opioid-naive patients; titration based on response; maximum 32 mg daily.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life: approximately 15-18 hours in healthy adults. Steady state is achieved by 3-5 days. In patients with hepatic impairment, half-life may be prolonged up to 24-27 hours.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Hepatic via CYP3A4 to hydromorphone and other inactive metabolites.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal: primarily as hydromorphone-3-glucuronide and unchanged drug (~40% as glucuronide conjugates, ~3% as unchanged hydromorphone). Fecal: minimal. Total renal clearance accounts for ~50% of drug elimination.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Approximately 20-30% bound to plasma proteins (primarily albumin).
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Volume of distribution (Vd): 90-120 L (approx. 1.3-1.7 L/kg), indicating extensive tissue distribution.
4-6 L/kg; large Vd indicates extensive tissue distribution
Extended-release tablet: approximately 40% oral bioavailability due to first-pass metabolism. Bioavailability relative to immediate-release hydromorphone is comparable.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
GFR 30-59 m L/min: reduce dose by 50%; GFR <30 m L/min: start with 4 mg every 24 hours and titrate cautiously.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh Class A or B: reduce dose by 25-50%; Child-Pugh Class C: avoid use or use with extreme caution with 50% dose reduction.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Not approved for pediatric use; safety and efficacy not established.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Start at lowest dose (4 mg every 24 hours) and titrate slowly due to increased sensitivity and risk of respiratory depression.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Serious, life-threatening, or fatal respiratory depression; risk of opioid addiction, abuse, and misuse; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Respiratory depression; addiction, abuse, and misuse; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; severe hypotension; gastrointestinal obstruction; seizure-prone patients; head injury; impaired renal or hepatic function.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected gastrointestinal obstruction (including paralytic ileus); hypersensitivity to hydromorphone or any component of the product.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Avoid grapefruit and grapefruit juice as they may increase hydromorphone levels. Avoid alcohol and any food containing alcohol, as it can potentiate CNS depression. No other significant food interactions reported; however, a high-fat meal may delay absorption but does not affect overall exposure.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
FDA Pregnancy Category C. First trimester: Limited data, but opioids cross placenta; risk of neural tube defects not established. Second/third trimester: Prolonged use may cause fetal opioid dependence, neonatal abstinence syndrome (NAS). High doses near delivery may cause neonatal respiratory depression.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Hydromorphone is excreted in breast milk; M/P ratio approximately 2.6. Relative infant dose ~0.5-2% of maternal weight-adjusted dose. Use with caution; monitor infant for sedation, respiratory depression, and withdrawal. Consider risk of infant opioid exposure.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Pregnancy may increase hydromorphone clearance due to increased renal blood flow and hepatic metabolism, potentially requiring higher or more frequent doses to maintain analgesia. However, no established guidelines; individualize dosing based on pain control and signs of respiratory depression. Avoid use during labor due to risk of neonatal respiratory depression.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
EXALGO (hydromorphone extended-release) is an opioid agonist indicated for pain severe enough to require daily, around-the-clock, long-term opioid treatment. Do not crush, chew, or dissolve tablets; this can cause rapid release and fatal overdose. Due to its high potency (5-7 times morphine), initiate cautiously in opioid-naïve patients. Use with naloxone available and educate on signs of respiratory depression. Avoid use in patients with significant respiratory depression, acute or severe bronchial asthma, or known or suspected paralytic ileus. Monitor for opioid-induced constipation and consider bowel regimen. EXALGO's QD dosing is convenient but requires strict adherence to 24-hour interval.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take EXALGO exactly as prescribed; do not take more than prescribed or more often than every 24 hours.,Swallow tablets whole; do not crush, chew, or dissolve them as this can cause a fatal overdose.,Avoid alcohol and any other central nervous system depressants (e.g., benzodiazepines, other opioids) unless directed by your doctor, as they increase risk of severe sedation and respiratory depression.,Store in a safe place out of reach of children and others; dispose of unused tablets via a drug take-back program.,Do not stop taking EXALGO abruptly without consulting your doctor; withdrawal symptoms may occur.,Seek emergency help if you experience trouble breathing, extreme drowsiness, or fainting.,Do not drive or operate heavy machinery until you know how EXALGO affects you.,Notify your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EXALGO vs ABSTRAL, answered by our medical review team.
EXALGO is a Opioid Analgesic that works by Mu-opioid receptor agonist; inhibits ascending pain pathways and alters pain perception and emotional response to pain.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EXALGO and ABSTRAL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EXALGO is: Initial: 8 mg orally every 24 hours for opioid-naive patients; titration based on response; maximum 32 mg daily.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EXALGO and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EXALGO is classified as Category C. FDA Pregnancy Category C. First trimester: Limited data, but opioids cross placenta; risk of neural tube defects not established. Second/third trimester: Prolonged use may cause fe. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.